Also known as Erythropoietin · Epoetin alfa · Epogen · Procrit · recombinant human erythropoietin · rhEPO
A glycoprotein hormone that drives red-blood-cell production — a recombinant biologic famous in medicine for treating anemia and infamous in sport for blood doping.
Erythropoietin is the hormone the kidneys release to tell the bone marrow to make more red blood cells. It is a 165-amino-acid glycoprotein, roughly 30–34 kDa once its sugar chains are counted, and like other glycoprotein hormones its carbohydrate is not optional — the glycosylation governs its stability and circulating half-life. Recombinant versions (epoetin alfa and its relatives) are produced in mammalian cells so that human-like glycosylation occurs, and beyond its core role in red-cell production it has a substantial research literature in tissue protection.
EPO is a glycoprotein, and that places it firmly in the biologic tier of this catalog. Its 165-residue chain folds into a four-helix bundle (the same architectural family as growth hormone) and is decorated with three N-linked and one O-linked glycan. Those sugars are functionally decisive: more heavily glycosylated, engineered versions (such as darbepoetin) circulate far longer. This is why EPO is made in mammalian cell culture rather than bacteria — only a eukaryotic cell adds the human-style glycosylation the molecule needs.
In medicine it is well established and genuinely important: recombinant EPO treats the anemia of chronic kidney disease, chemotherapy, and other marrow-suppressed states, sparing transfusions for millions. Its receptor turns up in the nervous system and elsewhere, which has driven a long research thread into EPO as a cytoprotective and neuroprotective agent after ischemic injury — promising in models, unproven as therapy.
Then there is the doping. EPO became the defining drug of endurance-sport scandals: by raising red-cell mass it boosts oxygen delivery and stamina, and it sat at the center of professional cycling’s doping era. The misuse carries real danger — thickened blood raises the risk of clots, stroke, and heart attack — and the same caution emerged in medicine, where trials showed that over-correcting hemoglobin to normal or high targets increased cardiovascular events and mortality. EPO is a clean example of a molecule whose reputation splits sharply between its legitimate, life-improving medical use and its dangerous performance misuse.
Binds the erythropoietin receptor on red-cell progenitors in the bone marrow, activating JAK2/STAT5 signaling that promotes their survival, proliferation, and maturation into erythrocytes — raising the blood’s oxygen-carrying capacity. The same receptor is expressed in other tissues, the basis for its cytoprotective research.
Behind every vial of EPO (Erythropoietin) is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how EPO (Erythropoietin), specifically, is brought into being.
On paper, EPO (Erythropoietin) weighs in at roughly 30,400 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
EPO (Erythropoietin) is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — EPO (Erythropoietin) plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of EPO (Erythropoietin) proves itself: identity confirmed by mass spectrometry against its ~30,400 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of EPO (Erythropoietin) — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
EPO is produced recombinantly in mammalian (CHO) cell culture so that its essential N- and O-linked glycosylation is human-like; its ~30–34 kDa mass is approximate and varies with glycosylation, so it has no single molecular formula. Characterization is glycoprotein-grade — glycan/isoform profiling, identity by mass spectrometry and peptide mapping, and cell-based potency — far beyond an HPLC purity figure.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Erythropoietin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Erythropoietin — a glycoprotein hormone, mainly from the kidneys, that signals the bone marrow to produce red blood cells. Recombinant EPO (epoetin alfa) treats anemia in kidney disease and chemotherapy.
It is a folded, glycosylated 165-amino-acid protein whose sugar chains are essential to its activity and half-life. It is produced in mammalian cells so that human-like glycosylation occurs — something bacterial peptide synthesis cannot do.
By increasing red-cell mass it raises oxygen delivery and endurance, which made it a notorious performance drug, especially in cycling. The misuse is dangerous — it thickens the blood and raises clot, stroke, and heart-attack risk.
No — this is a research and educational reference. EPO is a prescription biologic with significant cardiovascular risks when misused.